CARES Act Offers $100B in Relief to Hospitals/Health Systems…What Comes Next? | Deloitte US has been saved
Limited functionality available
by Anne Phelps, principal, US Health Care Regulatory leader, Deloitte & Touche LLP
The Coronavirus Aid, Relief, and Economic Security (CARES) Act was signed into law on March 27. The law—the largest stimulus package in US history—provides $2.2 trillion in financial relief to individuals, businesses, and the health care community. Specifically, the CARES Act includes a $100 billion cash infusion to hospitals and health systems directly or indirectly affected by the COVID-19 pandemic. The funding is equivalent to about one month of total US hospital operating revenue.1 While the CARES Act is the third piece of legislation enacted by the White House related to the novel coronavirus, it is the biggest and most far-reaching. Further federal funding is expected.
During an April 9 Dbrief webinar, we laid out some of the key provisions of this new law and tried to address some of the questions we’ve been hearing from our health care clients. Here’s what we don’t yet know: Will the funding only apply to hospitals that participate in Medicare and Medicaid? What will the application look like? We are awaiting those details, and guidance is expected any day. We also expect that checks will be in the mail in days or weeks rather than months.
In the meantime, here’s what we do know:
Hotspot hospitals are spending tremendous amounts of money and resources to treat COVID-19 patients. In other parts of the country, many hospitals are standing by with few or no COVID-19 patients but are also experiencing significant revenue losses as elective and non-life-threatening procedures are deferred. According to the law, health care entities that provide “diagnoses, testing, or care for individuals with possible or actual cases of COVID-19” are eligible for federal funding. Along with reimbursing hospitals for direct care expenses, money can also be used to offset costs related to the preparation of COVID-19 patients. This might include additional training for clinicians and other care providers, expanding capacity, or retrofitting facilities. The law also dedicates funding to life sciences companies that are developing vaccines and therapies to prevent or treat the illness, and manufacturers that produce devices used to care for COVID-19 patients.
The US Department of Health and Human Services (HHS) has been given broad discretion on how the funds are to be distributed. On April 10, HHS offered more detail about how the $100 billion would be distributed. On the same day, the agency began sending out its initial $30 billion directly to hospitals, health systems, and other facilities that received Medicare fee-for-service payments in 2019. Payments are be based on their total share of Medicare FFS payments that year. The funding isn’t a grant or a loan and does not need to be repaid. However, there is an attestation that must be signed, and hospitals must agree to terms and conditions, which include record-keeping requirements. Hospitals and health systems are also barred from engaging in balance billing for COVID-19 related treatments. The ban applies to patients covered by commercial, government or employer-sponsored coverage. As this and subsequent allocations of the $100 billion are sent out, we are urging our hospital and health system clients to create an audit trail by ensuring all COVID-19-related expenses are cataloged and documented using appropriate codes.
In addition to the $100 billion funding available through HHS, hospitals also can receive a 20 percent increase in Medicare reimbursement for diagnoses related to COVID-19 hospitalizations. Moreover, Section 3709 of the CARES Act temporarily suspends Medicare sequestration from May 1 until the end of the year. That means hospitals and health systems can expect a 2 percent increase in fee-for-service Medicare payments compared to what they otherwise would have received. Medicare recipients are also allowed to request a 90-day supply of medication rather than 30 days to help reduce the need to leave the home to pick up drugs.
In light of what we currently know about these funding and policy relief opportunities, finance departments should closely track services that have been deferred and revenue that is not coming through the door because of the virus. The more you can document, likely the better off you are going to be when it comes to funding.
What funding is available and what action should be taken?
This first wave of funding is already being distributed to Medicare providers. The second round of funding might expand to other types of facilities, while the last piece could be dedicated to expenses incurred by the uninsured. There are two other major buckets of federal relief funding for hospitals, health systems, and other health care stakeholders. They are:
What might come next?
Congress is crafting another economic stimulus package that will likely target small businesses. We could also see additional funding for hospitals and other health providers that continue to treat COVID-19 patients, as well as health facilities that remain empty.
There has also been concern about the number of people who have lost their jobs and their health coverage. Over a period of just four weeks, more than 22 million people in the US applied for unemployment benefits.2 While some people have lost health coverage, others might become uninsured if they can’t afford COBRA premiums without a regular paycheck (under COBRA, enrollees must pay 102 percent of the full cost of coverage, including the employer’s share). Lawmakers on Capitol Hill are discussing strategies to help people maintain some type of health coverage, including a House bill introduced April 14 that would help workers maintain employer-based coverage.3 This is an issue that might be addressed more specifically in the next stimulus package.
I have been amazed by the resilience of our health care community. I expect that once we emerge from this crisis, this sector will be more connected and far better prepared to meet future challenges. The road ahead is going to be long, but we will get to the other side and hopefully thrive there.
1. Responding To COVID-19: Using the CARES Act’s hospital fund to help the uninsured, achieve other goals, Health Affairs, April 11, 2020
2. Worst-Case Fears of 20%-Plus U.S. Jobless Rate Are Now Realistic, Bloomberg, April 14, 2020
3. Democrats offer bill to help unemployed stay on employer-based insurance, The Hill, April 14, 2020
Anne is a principal at Deloitte & Touche LLP in the Life Sciences and Health Care practice based in Washington, DC. As the US Health Care Regulatory leader for Deloitte, Anne manages the Health Care Strategic Regulatory Implementation Services practice where she works with clients to navigate the complex world of health care regulatory changes and helps them set their business priorities and strategic opportunities in the midst of a dynamic environment. Anne has nearly thirty years of health care policy experience in a broad range of legislative and regulatory issues. Anne serves as a strategic business advisor to numerous health care stakeholders – including providers, payers, employers, life sciences companies, and investors. Prior to her career in professional services, Anne served in the George W. Bush Administration as a Special Assistant to the President and the Chief Health Policy Advisor to the President for the Domestic Policy Council and as the Executive Director of the 2004 Republican National Platform Committee. Earlier in her career, Anne worked on Capitol Hill in the United States Senate for Senators Nancy Kassebaum and Bill Frist, M.D. and was instrumental in the drafting and passage of HIPAA and other insurance and public health laws. She spent nearly five years at the National Institutes of Health in a variety of health policy and legislative roles due to her background in bioethics. Anne is a frequent speaker and author on health care regulatory and legislative issues. She has provided numerous presentations to corporate executives and board members, large policy forums, federal agencies, members of Congress, and congressional staff. Anne holds a Master of Arts in public policy from The George Washington University and a Bachelor of Arts in English from the University of Dayton (summa cum laude).